CXL wins FDA approval, so prepare to code – Ophthalmology Management

Corneal collagen cross-linking is a fairly new procedure to treat certain corneal diseases. As is often the case, there are lots of questions about coverage from third-party payers at this point.

This article addresses the following questions:

• What is corneal collagen cross-linking?
• What conditions are treated with CXL?
• Has CXL been approved by the FDA?
• What CPT code describes CXL?
• Is CXL covered by Medicare or health insurance?
• If coverage of CXL is unlikely or uncertain, how should we proceed?

This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Executive Vice-President, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below:

http://www.ophthalmologymanagement.com/articleviewer.aspx?articleID=114345